Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21918916 | 0.97 | NR1I2 (0.38) | NR1I2TP53CA12CA1CA2 | |
| SCHEMBL19997545 | 0.76 | ALDH1A1 (0.30) | — | |
| SCHEMBL21026101 | 0.73 | NR1I2 (0.33) | NR1I2 | |
| SCHEMBL24023229 | 0.73 | NR1I2 (0.33) | NR1I2 | |
| SCHEMBL21899704 | 0.73 | GLP1R (0.33) | — | |
| SCHEMBL21899253 | 0.72 | GLP1R (0.35) | — | |
| SCHEMBL21031499 | 0.72 | NR1I2 (0.32) | NR1I2 | |
| SCHEMBL22481779 | 0.69 | GLP1R (0.30) | CA12CA1CA2CA9 | |
| SCHEMBL30107919 | 0.65 | NR1I2 (0.43) | NR1I2TP53CA2 | |
| SCHEMBL21854473 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059795-B2 | Androgen receptor modulators and methods for their use | ESSA PHARMA, INC. (CA) | 2021-07-13 | — | — | US | disclosed |
| US-20200247763-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247763-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, NR5A1, CYP17A1 | NR1I2 34/4885TP53 706/4885CA12 969/4885 |
| US-11059795-B2 | Androgen receptor modulators and methods for their use | AR, NR5A1, CYP17A1 | NR1I2 34/4885TP53 706/4885CA12 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.